Dissecting the modulatory functions of interleukin-17 in alzheimer's disease
Active Grant Awarded Last action
- Award ID
- R01AG080738
- Recipient
-
President And Fellows Of Harvard College UEI JDLVAVGYJQ21 Part of Harvard College President & Fellows Of
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,498,259
Award facts
- Assistance listing
- 93.AGR National Institute on Aging Research Projects
- Completion date 45% complete
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Grant R01AG080738 to President and Fellows of Harvard College, doing business as Harvard Medical School, on January 16, 2026, obligating $1.498259 million under the National Institute on Aging Research Projects program (CFDA 93.AGR). The grant funds research on the modulatory functions of interleukin-17 in Alzheimer's disease, assessing the contributing roles of a triad of gut bacteria, peripheral Th17 cells, and IL-17 receptor signaling in the brain. The period of performance ends November 30, 2027, and place of performance is Boston, MA 02115.
The award includes one federal grant sub-award, dated April 16, 2026, to Massachusetts Institute of Technology (MIT) for work in the Choi lab. The sub-awardee will evaluate brain phenotypes in mouse models of neurodegenerative disorders, conduct behavior analyses of IL-17a, Th17 cells, and the gut microbiome's effect on Alzheimer's-related phenotypes, and evaluate IL-17RA expression in the brain and its function in Alzheimer's pathophysiology. Dr. Choi directly oversees one postdoctoral fellow and one research technician and coordinates with Dr. Jun Huh.
Description
- Abstract
- Alzheimer's disease (ad) is one of the most common causes of dementia, affecting over 5 million elderly patients in 2020. The affected patient number will likely grow in the united states and reach 10 million by 2040, representing a significant challenge to public health care. IT is thus imperative to find novel ways that offer mechanistic insights into the onset and the progression of ad. While a growing body of evidence indicates the critical function of innate immune systems in ad, relatively few studies investigated mechanisms by which adaptive immune cells contribute to the pathogenesis of ad. Along with genetic factors, environmental factors are critical contributors to driving neurodegenerative disorders, including ad. GUT microbes, which have been extensively studied for their roles in shaping the host's immune function, are being recognized as one of these non-genetic factors that define a threshold to either maintaining homeostasis or developing diseases. Intriguingly, ad patients often display GUT dysbiosis, suggesting that the make-up of GUT-residing bacteria may affect the development and progression of ad. While many studies in recent years have shown that GUT-residing bacteria and immune cells affect brain function, the underlying mechanisms by which GUT bacteria empower peripheral immune cells to influence ad-related phenotypes are unknown. Among the many immune cell types, TH17 cells are uniquely positioned to relay signals from GUT-residing bacteria to the brain. These cells are induced in the GUT mucosa in response to a commensal bacterium and can migrate into the meninges. We and others have also shown that a receptor for IL-17A, namely IL-17RA, is expressed in the adult brain and facilitates the communication between the immune and nervous systems. In the proposed application, we will assess the contributing roles of the triad of GUT bacteria-peripheral TH17 cells-brain IL-17RA in promoting ad-related pathologies and cognitive decline. We will first identify the role of IL-17A-producing cells in promoting ad-related pathogenesis and determine the contributing roles of GUT- residing bacteria that enhance TH17 cell biogenesis in the development of ad. Second, we will uncover the underlying mechanisms by which IL-17A affects brain cells during ad development. Successful completion of this study will likely lead to future human studies identifying preventive and therapeutic measures, such as probiotics or blocking antibodies, to suppress the IL-17A responses in patients with a high risk of developing ad-related cognitive decline.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $743,017 | |
| Amendment | $75,523 | |
| Original award | $679,719 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Massachusetts Institute Of Technology | $274,210 |
Quick answers
Who received award R01AG080738?
R01AG080738 was awarded to President And Fellows Of Harvard College by National Institute on Aging (National Institutes of Health) on January 16, 2026.
How much is award R01AG080738 worth?
$1,498,259 has been obligated on R01AG080738.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award